Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237594 · ClinicalTrials.gov registry record · Phase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
A Phase 1 study, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT07237594 is a Phase 1 study that is actively recruiting participants, run by Duke University. The registered enrollment target is 4 participants.
The verdict
NCT07237594, a Phase 1 study, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.
Interventions
- DRUG Secukinumab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07237594
The ClinicalTrials.gov registry entry for NCT07237594 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab Injection is the first listed.
NCT07237594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07237594 about?
NCT07237594 is a clinical study titled "IL-17 Blockade to Decrease irAEs (REPLAY)". The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune...
What is the current status of trial NCT07237594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2026-03-12. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07237594?
The interventions under investigation include: Secukinumab Injection (DRUG).
Who is sponsoring clinical trial NCT07237594?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.